Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Thromboembolism(TE) is a common complication in patients withmultiple myeloma (MM). Immunomodulatory agents, e.g., thalidomide, have expanded the therapeutic options for treating myeloma; however, Western countries report a high incidence of thrombosis in thalidomide-treated MM patients who lack thromboprophylaxis. A Korean trial reported low TE incidence in thalidomide-treated myeloma patients (39 % were given aspirin prophylactically).We aimed to elucidate the TE frequency in MM patients in Taiwan who were treated with thalidomide without TE prophylaxis. We retrospectively collected the records of MM patients who had used thalidomide from a single institute between 2004 and 2010, combined these records with two other Taiwanese studies, and compared all three with the Korean trial. In the current Taiwanese series, five of 144 patients (3.5%) developed TE as follows: three (2.1 %) were venous and two (1.3 %) were arterial. Only 6.1 % of the patients had undergone TE prophylaxis, which is less than in the Korean trial (38.9 %, p<0.05). Of the patients in the relapsed/refractory cohort (n=114) who were given thalidomide alone, none (0/52) developed venous TE (VTE); however, two patients (2/35, 5.7 %) who were given thalidomide-dexamethasone as a salvage treatment developed VTE. In the thrombosis cohort, four patients (80 %) were treated with thalidomide plus dexamethasone. In conclusion, the frequency of thalidomide-related TE in myeloma patients without effective TE prophylaxis was low in Taiwan. In relapsed/refractory myeloma patients, the VTE frequency was slightly lower compared with Western patients irrespective of treatment with thalidomide alone or combined with dexamethasone. Even in low TE incidence areas, thalidomide combined with dexamethasone was more thrombogenic compared with others.

Original languageEnglish
Pages (from-to)1773-1778
Number of pages6
JournalAnnals of Hematology
Volume91
Issue number11
DOIs
Publication statusPublished - 2012 Nov 1

Fingerprint

Thalidomide
Thromboembolism
Taiwan
Incidence
Dexamethasone
Thrombosis
Salvage Therapy
Venous Thromboembolism
Aspirin

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{095189c28a4143a28e8d8f913eb8783d,
title = "Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan",
abstract = "Thromboembolism(TE) is a common complication in patients withmultiple myeloma (MM). Immunomodulatory agents, e.g., thalidomide, have expanded the therapeutic options for treating myeloma; however, Western countries report a high incidence of thrombosis in thalidomide-treated MM patients who lack thromboprophylaxis. A Korean trial reported low TE incidence in thalidomide-treated myeloma patients (39 {\%} were given aspirin prophylactically).We aimed to elucidate the TE frequency in MM patients in Taiwan who were treated with thalidomide without TE prophylaxis. We retrospectively collected the records of MM patients who had used thalidomide from a single institute between 2004 and 2010, combined these records with two other Taiwanese studies, and compared all three with the Korean trial. In the current Taiwanese series, five of 144 patients (3.5{\%}) developed TE as follows: three (2.1 {\%}) were venous and two (1.3 {\%}) were arterial. Only 6.1 {\%} of the patients had undergone TE prophylaxis, which is less than in the Korean trial (38.9 {\%}, p<0.05). Of the patients in the relapsed/refractory cohort (n=114) who were given thalidomide alone, none (0/52) developed venous TE (VTE); however, two patients (2/35, 5.7 {\%}) who were given thalidomide-dexamethasone as a salvage treatment developed VTE. In the thrombosis cohort, four patients (80 {\%}) were treated with thalidomide plus dexamethasone. In conclusion, the frequency of thalidomide-related TE in myeloma patients without effective TE prophylaxis was low in Taiwan. In relapsed/refractory myeloma patients, the VTE frequency was slightly lower compared with Western patients irrespective of treatment with thalidomide alone or combined with dexamethasone. Even in low TE incidence areas, thalidomide combined with dexamethasone was more thrombogenic compared with others.",
author = "Shang-Yin Wu and Yu-Min Yeh and Ya-Ping Chen and Wu-Chou Su and Tsai-Yun Chen",
year = "2012",
month = "11",
day = "1",
doi = "10.1007/s00277-012-1506-2",
language = "English",
volume = "91",
pages = "1773--1778",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan

AU - Wu, Shang-Yin

AU - Yeh, Yu-Min

AU - Chen, Ya-Ping

AU - Su, Wu-Chou

AU - Chen, Tsai-Yun

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Thromboembolism(TE) is a common complication in patients withmultiple myeloma (MM). Immunomodulatory agents, e.g., thalidomide, have expanded the therapeutic options for treating myeloma; however, Western countries report a high incidence of thrombosis in thalidomide-treated MM patients who lack thromboprophylaxis. A Korean trial reported low TE incidence in thalidomide-treated myeloma patients (39 % were given aspirin prophylactically).We aimed to elucidate the TE frequency in MM patients in Taiwan who were treated with thalidomide without TE prophylaxis. We retrospectively collected the records of MM patients who had used thalidomide from a single institute between 2004 and 2010, combined these records with two other Taiwanese studies, and compared all three with the Korean trial. In the current Taiwanese series, five of 144 patients (3.5%) developed TE as follows: three (2.1 %) were venous and two (1.3 %) were arterial. Only 6.1 % of the patients had undergone TE prophylaxis, which is less than in the Korean trial (38.9 %, p<0.05). Of the patients in the relapsed/refractory cohort (n=114) who were given thalidomide alone, none (0/52) developed venous TE (VTE); however, two patients (2/35, 5.7 %) who were given thalidomide-dexamethasone as a salvage treatment developed VTE. In the thrombosis cohort, four patients (80 %) were treated with thalidomide plus dexamethasone. In conclusion, the frequency of thalidomide-related TE in myeloma patients without effective TE prophylaxis was low in Taiwan. In relapsed/refractory myeloma patients, the VTE frequency was slightly lower compared with Western patients irrespective of treatment with thalidomide alone or combined with dexamethasone. Even in low TE incidence areas, thalidomide combined with dexamethasone was more thrombogenic compared with others.

AB - Thromboembolism(TE) is a common complication in patients withmultiple myeloma (MM). Immunomodulatory agents, e.g., thalidomide, have expanded the therapeutic options for treating myeloma; however, Western countries report a high incidence of thrombosis in thalidomide-treated MM patients who lack thromboprophylaxis. A Korean trial reported low TE incidence in thalidomide-treated myeloma patients (39 % were given aspirin prophylactically).We aimed to elucidate the TE frequency in MM patients in Taiwan who were treated with thalidomide without TE prophylaxis. We retrospectively collected the records of MM patients who had used thalidomide from a single institute between 2004 and 2010, combined these records with two other Taiwanese studies, and compared all three with the Korean trial. In the current Taiwanese series, five of 144 patients (3.5%) developed TE as follows: three (2.1 %) were venous and two (1.3 %) were arterial. Only 6.1 % of the patients had undergone TE prophylaxis, which is less than in the Korean trial (38.9 %, p<0.05). Of the patients in the relapsed/refractory cohort (n=114) who were given thalidomide alone, none (0/52) developed venous TE (VTE); however, two patients (2/35, 5.7 %) who were given thalidomide-dexamethasone as a salvage treatment developed VTE. In the thrombosis cohort, four patients (80 %) were treated with thalidomide plus dexamethasone. In conclusion, the frequency of thalidomide-related TE in myeloma patients without effective TE prophylaxis was low in Taiwan. In relapsed/refractory myeloma patients, the VTE frequency was slightly lower compared with Western patients irrespective of treatment with thalidomide alone or combined with dexamethasone. Even in low TE incidence areas, thalidomide combined with dexamethasone was more thrombogenic compared with others.

UR - http://www.scopus.com/inward/record.url?scp=84867335330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867335330&partnerID=8YFLogxK

U2 - 10.1007/s00277-012-1506-2

DO - 10.1007/s00277-012-1506-2

M3 - Article

C2 - 22706703

AN - SCOPUS:84867335330

VL - 91

SP - 1773

EP - 1778

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 11

ER -